The clinical potential of Affibody-based inhibitors of C5 for therapeutic complement disruption

Expert Review of Proteomics

Volumn 13, Issue 3, 2016, Pages 241-243

  Berglund, Magnus M ^a   Stromberg, Patrik ^a  

^a BIOVITRUM AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AFFIBODY; COMPLEMENT COMPONENT C5 INHIBITOR; ECULIZUMAB; UNCLASSIFIED DRUG; COMPLEMENT COMPONENT C5; MONOCLONAL ANTIBODY;

COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT INHIBITION; EDITORIAL; GLOMERULUS FILTRATION; HUMAN; MOLECULAR SIZE; NONHUMAN; PROTEIN TARGETING; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT C5; HUMANS;

EID: 84960379919     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/14789450.2016.1148604     Document Type: Editorial

References (20)

1. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for Affibody molecules. J Mol Biol. 2010; 398 (2): 232-247.
2. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010; 584 (12): 2670-2680.
3. Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In-or 68Ga-labeled Affibody molecules. J Nucl Med. 2010; 51 (6): 892-897.
4. Orlova A, Tran T, Widstrom C, et al. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med. 2007; 20 (3): 397-404.
5. Kontermann RE. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 2011; 22 (6): 868-876.
6. Bhat AS, Rabuka D, Bleck G. The next step in homogenous bioconjugate development: optimizing payload placement and conjugate composition [Internet]. BioProcess International. 2014. [cited 2014 Oct 15]. http://www.bioprocessintl.com/manufacturing/antibody-non-antibody/next-step-homogenous-bioconjugate-development-optimizing-payload-placement-conjugate-composition/
7. Strömberg P, Berglund MM, Ekholm C., et al. Development of Affibody® C5 inhibitors for versatile and efficient therapeutic targeting of the terminal complement pathway. Mol Immunol. 2014; 61 (2): 256.
8. Andersen JT, Pehrson R, Tolmachev V, et al. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J Biol Chem. 2011; 286 (7): 5234-5241.
9. Jonsson A, Dogan J, Herne N, et al. Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng Des Sel. 2008; 21 (8): 515-527.
10. Zurdo J, Arnell A, Obrezanova O, et al. Early implementation of QbD in biopharmaceutical development: a practical example. Biomed Res Int. 2015; 2015: 605427.
11. Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010; 11 (9): 785-797.
12. Merle NS, Noe R, Halbwachs-Mecarelli L, et al. Complement system Part II: role in immunity. Front Immunol. 6 (257): 2015.
13. Owen EP, Wurzner R, Leisegang F, et al. A complement C5 gene mutation, c.754G>A:p.A252T, is common in the Western Cape, South Africa and found to be homozygous in seven percent of Black African meningococcal disease cases. Mol Immunol. 2015; 64 (1): 170-176.
14. Coyle D, Cheung MC, Evans GA. Opportunity cost of funding drugs for rare diseases: the cost-effectiveness of eculizumab in paroxysmal nocturnal hemoglobinuria. Med Decis Making. 2014; 34 (8): 1016-1029.
15. Risitano AM. Current and future pharmacologic complement inhibitors. Hematol Oncol Clin North Am. 2015; 29 (3): 561-582.
16. Howard JF Jr., Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013; 48 (1): 76-84.
17. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. 2016;13(1):70-83.
18. Morgan BP, Harris CL. Complement, a target for therapy in inflammatory and degenerative diseases. Nat Rev Drug Discov. 2015; 14 (12): 857-877.
19. Johnson CK, Leca N. Eculizumab use in kidney transplantation. Curr Opin Organ Transplant. 2015; 20 (6): 643-651.
20. Weber BH, Charbel Issa P, Pauly D, et al. The role of the complement system in age-related macular degeneration. Dtsch Arztebl Int. 2014; 111 (8): 133-138.